Brett P Monia - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Brett P Monia

Showing results (121-130 of 147) with videos related to

Pageof 15

Sort By:

JCI Insight|June 21, 2019

Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic miceMariam Aghajan, Sheri L Booten, Magnus Althage, et al.

Cell Metabolism|February 7, 2006

miR-122 regulation of lipid metabolism revealed by in vivo antisense targetingChristine Esau, Scott Davis, Susan F Murray, et al.

Proceedings of the National Academy of Sciences of the United States of America|June 25, 2009

SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic ratsDerek M Erion, Shin Yonemitsu, Yongzhan Nie, et al.

The Journal of Biological Chemistry|May 5, 2007

Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage diseaseKyle W Sloop, Aaron D Showalter, Amy L Cox, et al.

Nucleic Acid Therapeutics|February 12, 2020

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated ThrombocytopeniaPadmaKumar Narayanan, Brian R Curtis, Lijiang Shen, et al.

Science Translational Medicine|June 16, 2017

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRASSarah J Ross, Alexey S Revenko, Lyndsey L Hanson, et al.

Journal of Medicinal Chemistry|April 28, 2010

Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissueEdward V Wancewicz, Martin A Maier, Andrew M Siwkowski, et al.

Blood|July 27, 2011

Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domainNetanel A Horowitz, Elizabeth A Blevins, Whitney M Miller, et al.

ESC Heart Failure|December 7, 2020

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 dataNicholas J Viney, Shuling Guo, Li-Jung Tai, et al.

Journal of Medicinal Chemistry|October 14, 2005

Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acidKlaus Albertshofer, Andrew M Siwkowski, Edward V Wancewicz, et al.

Pageof 15

Search research articles

Showing results (121-130 of 147) with videos related to

Sort By:

Pageof 15

JCI Insight|June 21, 2019

Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic miceMariam Aghajan, Sheri L Booten, Magnus Althage, et al.

Cell Metabolism|February 7, 2006

miR-122 regulation of lipid metabolism revealed by in vivo antisense targetingChristine Esau, Scott Davis, Susan F Murray, et al.

Proceedings of the National Academy of Sciences of the United States of America|June 25, 2009

SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic ratsDerek M Erion, Shin Yonemitsu, Yongzhan Nie, et al.

The Journal of Biological Chemistry|May 5, 2007

Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage diseaseKyle W Sloop, Aaron D Showalter, Amy L Cox, et al.

Nucleic Acid Therapeutics|February 12, 2020

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated ThrombocytopeniaPadmaKumar Narayanan, Brian R Curtis, Lijiang Shen, et al.

Science Translational Medicine|June 16, 2017

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRASSarah J Ross, Alexey S Revenko, Lyndsey L Hanson, et al.

Journal of Medicinal Chemistry|April 28, 2010

Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissueEdward V Wancewicz, Martin A Maier, Andrew M Siwkowski, et al.

Blood|July 27, 2011

Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domainNetanel A Horowitz, Elizabeth A Blevins, Whitney M Miller, et al.

ESC Heart Failure|December 7, 2020

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 dataNicholas J Viney, Shuling Guo, Li-Jung Tai, et al.

Journal of Medicinal Chemistry|October 14, 2005

Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acidKlaus Albertshofer, Andrew M Siwkowski, Edward V Wancewicz, et al.

Pageof 15